Abstract: Metastasis constantly occurs in the majority of cases of primary breast cancer at late stage or following surgical treatment. Survivin, a member of the inhibitor of apoptosis protein family, has long been recognized as a promising anticancer target, but its antitumor effects remain largely unexplored. In order to elucidate the role of survivin in breast cancer metastasis, short interfering RNA (siRNA) was used in the present study to specifically downregulate survivin expression in the murine breast cancer cell line 4T1. The results demonstrated that blocking the expression of survivin by siRNA inhibited the proliferation, migration and invasion abilities of murine breast cancer cells in vitro. Vascular endothelial growth factor (VEGF)-C is a lymphatic endothelial cell-stimulating factor that may lead to the formation of lymphatic vessels in lymph nodes. In the present study, the inhibition of survivin by siRNA was able to reduce the overexpression of VEGF-C in 4T1 cells. Furthermore, intratumoral injections of the survivin-siRNA significantly inhibited the growth of orthotopically transplanted 4T1 tumors in vivo. In addition, the number of pulmonary metastases and the microlymphatic vessel density were significantly reduced in vivo, following transfection with survivin-siRNA. The results of the present study suggested that the Akt/hypoxia-inducible factor-1α signaling pathway participates in the survivin-mediated downregulation of VEGF-C expression observed in breast cancer cells treated with survivin-siRNA. Therefore, the use of siRNA specifically targeting survivin may be a potential anticancer method in the future.
Introduction
Metastasis—the spread of cancer from the primary site to distant organs—is responsible for approximately 90% of breast cancer deaths. Current treatments like surgery and chemotherapy often fail to prevent this spread, particularly through the lymphatic system.
This research focuses on survivin, a member of the "inhibitor of apoptosis" (IAP) protein family. Survivin is highly expressed in most cancers but nearly absent in healthy adult tissues, making it an ideal therapeutic target. While its role in preventing cell death was known, its specific contribution to the mechanical spread of breast cancer and its relationship with lymphatic growth factors like VEGF-C remained poorly understood.
Methods
The study employed a combination of in vitro (cell culture) and in vivo (animal model) techniques. The researchers used the 4T1 murine breast cancer cell line, which is known for its high metastatic potential, mimicking human Stage IV breast cancer. Specific siRNAs were designed to target and degrade survivin mRNA, with "scrambled" siRNA used as a negative control.
Molecular analysis included qPCR and Western blotting to measure mRNA and protein levels of survivin, VEGF-C, and key signaling molecules (Akt, p-Akt, and HIF-1α). Functional assays, such as MTT and Transwell assays, evaluated cell proliferation, migration, and invasion. In the animal study, 4T1 cells were orthotopically transplanted into the mammary fat pads of BALB/c mice, which then received intratumoral injections of survivin-siRNA.
Key Results
The application of survivin-siRNA led to a significant reduction in both mRNA and protein levels of survivin in 4T1 cells. Western blot analysis confirmed a clear decrease in protein expression over 24, 48, and 72 hours compared to untreated (UT) and scrambled siRNA (siRNAscr) controls.
Quantitative analysis showed that survivin-siRNA reduced survivin protein levels by over 60% at 48 hours. This knockdown was statistically significant across all time points measured, as shown in the relative expression charts below.
Functionally, this reduction led to a time-dependent inhibition of cell proliferation and a ~50% reduction in the number of cells able to invade through a Matrigel matrix. In vivo, intratumoral injection of survivin-siRNA significantly slowed tumor volume growth compared to controls (approx. 1.0 cm³ vs 2.0 cm³ after 18 days) and halved the number of lung metastatic colonies. Furthermore, the density of lymphatic vessels (MLVD) in the tumors was significantly lower, confirming that silencing survivin prevents the tumor from building the infrastructure needed to spread.
Discussion and Insights
The study reveals that survivin is more than just a "life guard" preventing cell death; it is a key driver of the cellular machinery required for migration and invasion. A critical finding is the Survivin-VEGF-C Link: when survivin was knocked down, levels of VEGF-C (a primary driver of lymphangiogenesis) plummeted.
The authors identified the Akt/HIF-1α pathway as the molecular bridge. Survivin appears to trigger the phosphorylation of Akt, which in turn stabilizes HIF-1α, a transcription factor that activates the VEGF-C gene. This provides a clear molecular map of how a single protein can orchestrate complex metastatic processes.
While promising, challenges remain. Intratumoral injections are effective in a lab setting but difficult for treating systemic metastasis in humans, necessitating the development of targeted systemic delivery vehicles like nanoparticles. Additionally, while the 4T1 model is a robust proxy for human metastatic breast cancer, clinical trials are required to see if the Akt/HIF-1α/VEGF-C axis operates identically in human patients.
Summary updated